WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS
Weight gain and metabolic alterations have been reported with integrase strand transfer inhibitor (INSTI)-based antiretroviral (ARV) regimens. Long-acting (LA) cabotegravir (CAB), an INSTI, and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor, constitute a highly effective 2-drug regimen administered intramuscularly monthly or every 2 months for the maintenance of virologic suppression. Weight and lipid changes over…